SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT00096746

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

An Exploratory Study of the Effect of the Atazanavir (ATV) I50L Mutation on Subsequent Treatment Response

This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.

NCT00096746 HIV Infection
MeSH: HIV Infections

2 Interventions

Name: LPV/RTV + 2NRTIs

Description: Tablets, Oral, Variable, Twice daily, 48 weeks.

Type: Drug

A1

Name: LPV/RTV + 2NRTIs

Description: Tablets, Oral, Variable, Twice daily, 48 weeks.

Type: Drug

A2

Primary Outcomes

Measure: The log10 HIV RNA change from baseline for each cohort.

Time: through Week 48

Secondary Outcomes

Measure: Evaluate proportion of patients with plasma HIV RNA <50 copies/mL

Time: at Weeks 24, 48, 72, and 96.
Time Perspective: Prospective

Cohort

There is one SNP

SNPs

1 I50L

An Exploratory Study of the Effect of the Atazanavir (ATV) I50L Mutation on Subsequent Treatment Response. --- I50L ---


HPO Nodes